Takeda opens new cell therapy manufacturing facility

By The Science Advisory Board staff writers

September 15, 2020 -- Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters in Boston.

The company said that the new facility will provide end-to-end R&D capabilities and accelerate its efforts to develop next-generation cell therapies. These initiatives are initially focused on oncology, but there's potential to expand into other therapeutic areas, Takeda said.

Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...
R&D Alliance begin I-Spy COVID trial
A collaborative research effort that includes the U.S. government and leading pharmaceutical companies has launched a clinical trial to investigate a...
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...
Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.
Egle, Takeda collaborate on anti-Treg immunotherapies
Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cells (Treg) targets, against which...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter